MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
May 18 2022 - 4:18PM
MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a
transformational placental biologics company, today filed an
investor presentation with the U.S. Securities and Exchange
Commission in connection with its 2022 Annual Meeting of
Shareholders, which is scheduled to be held on June 7, 2022. The
presentation, and other important shareholder materials, are
available at www.VoteMIMEDX.com.
In the presentation, MIMEDX outlines the
significant progress the Company has made over the last three years
under its current leadership team and provides transparency around
a number of topics and initiatives pertinent to shareholders,
including:
- Strategy for Long-Term
Value Creation: MIMEDX has taken decisive action to
successfully sustain, stabilize and grow the Company over the last
three years, and has a clear strategy for long-term shareholder
value creation. MIMEDX recently announced a third consecutive
quarter of double-digit growth in its Advanced Wound Care &
Surgical Recovery products, demonstrating strong execution. In
addition, the realignment of the Company’s internal business
structure positions MIMEDX to further expand, innovate, and drive
sustained growth, and also accelerate the start of trial enrollment
in its Knee Osteoarthritis clinical trial program.
- Corporate Governance
Practices and Board Qualifications: MIMEDX’s Board has
been entirely reconstituted since 2019 and is made up of nine
highly qualified directors with the critical skills, life-sciences
experience and business acumen to oversee the Company’s strategy.
The Board has adopted approximately 70 best-practice and
shareholder friendly corporate governance reforms over the last
three years and resolved all legacy Company issues, demonstrating
its commitment to best-in-class governance practices.
- Executive
Compensation: MIMEDX’s executive compensation, determined
in partnership with an independent consultant, is based on a
philosophy of organizational and individual performance and is
aligned with shareholder value through performance factors,
including revenue growth, and significant equity-based portions of
total compensation. It is well within the range of MIMEDX peers and
is closely aligned with shareholder interests. For example, in part
due to the decline in the Company’s stock price, none of MIMEDX’s
executive officers received annual cash bonuses at their 2021
target levels.
|
Your Vote Is Important, No Matter How Many or How Few
Shares You Own You can vote by Internet, telephone or
by signing and dating the WHITE proxy
card and mailing it in the envelope provided. If you have any
questions about how to vote your shares, or need additional
assistance, please contact: MORROW
SODALI MDXG@investor.Morrowsodali.com (203)
658-9400 or Toll-Free (800) 662-5200 |
|
About MIMEDX
MIMEDX is a transformational placental biologics
company, developing and distributing placental tissue allografts
with patent-protected, proprietary processes for multiple sectors
of healthcare. As a pioneer in placental tissue engineering, we
have both a commercial business, focused on addressing the needs of
patients with acute and chronic non-healing wounds, and a promising
late-stage pipeline targeted at decreasing pain and improving
function for patients with degenerative musculoskeletal conditions.
We derive our products from human placental tissues and process
these tissues using our proprietary methods, including the
PURION® process. We employ Current Good Tissue Practices,
Current Good Manufacturing Practices, and terminal sterilization to
produce our allografts. MIMEDX has supplied over two million
allografts, through both direct and consignment shipments. For
additional information, please visit www.mimedx.com.
Important Cautionary Statement
This press release includes forward-looking
statements. Statements regarding: (i) our belief that the long term
strategy we have chosen is in the best interests of our
shareholders; (ii) our belief that as we continue to execute
against our stated objectives and navigate our next phase of
growth, we are well positioned for the future; and (iii) our belief
that the experience, expertise and commitment of the MIMEDX
leadership team, as overseen by our Board of Directors, will help
position the Company for further future success and value creation.
Additional forward-looking statements may be identified by words
such as "believe," "expect," "may," "plan," “goal,” “outlook,”
"potential," "will," "preliminary," and similar expressions, and
are based on management's current beliefs and expectations.
Forward-looking statements are subject to risks
and uncertainties, and the Company cautions investors against
placing undue reliance on such statements. Actual results may
differ materially from those set forth in the forward-looking
statements. Factors that could cause actual results to differ from
expectations include: (i) future sales are uncertain and are
affected by competition, access to customers, patient access to
healthcare providers, and many other factors; (ii) the status,
timing, results and expected results of the Company’s clinical
trials, planned regulatory submissions and regulatory approvals,
and our expectations regarding our ability to potentially
accelerate the timing of any trial or regulatory submission, depend
on a number of factors including favorable trial results, patient
access, and our ability to manufacture in accordance with Current
Good Manufacturing Practices (CGMP) and appropriate chemistry and
manufacturing controls; (iii) the Company may change its plans due
to unforeseen circumstances, or delays in analyzing and auditing
results, and may delay or alter the timeline for future trials,
analyses, or public announcements; (iv) our access to hospitals and
health care provider facilities could be restricted as a result of
the ongoing COVID-19 pandemic or other factors; (v) the results of
scientific research are uncertain and may have little or no value;
(vi) our ability to sell our products in other countries depends on
a number of factors including adequate levels of reimbursement,
regulatory approvals, market acceptance of novel therapies, and our
ability to build and manage a direct sales force or third party
distribution relationship; (vii) the effectiveness of amniotic
tissue as a therapy for particular indications or conditions is the
subject of further scientific and clinical studies; and (viii) we
may alter the timing and amount of planned expenditures for
research and development based on the results of clinical trials
and other regulatory developments. The Company describes additional
risks and uncertainties in the Risk Factors section of its most
recent annual report and quarterly reports filed with the
Securities and Exchange Commission. Any forward-looking statements
speak only as of the date of this press release and the Company
assumes no obligation to update any forward-looking statement.
Important Additional
Information
The Company, its directors, director nominees
and certain of its executive officers are participants in the
solicitation of proxies from the Company’s shareholders in
connection with the 2022 annual meeting of shareholders (the “2022
Annual Meeting”). The Company has filed a definitive proxy
statement and a WHITE proxy card with the
Securities and Exchange Commission (the “SEC”) in connection with
any such solicitation of proxies from the Company’s shareholders.
SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE
PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND
ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR
ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. The Company’s
definitive proxy statement for the 2022 Annual Meeting contains
information regarding the direct and indirect interests, by
security holdings or otherwise, of the Company’s directors,
director nominees and executive officers in the matters to be acted
upon at the 2022 Annual Meeting. Information regarding subsequent
changes to their holdings of the Company’s securities can be found
in the SEC filings on Forms 3, 4 and 5, which are available on the
Company’s website at www.mimedx.com or through the SEC’s website at
www.sec.gov. Information can also be found in the Company’s other
SEC filings, including its Annual Report on Form 10-K for the year
ended December 31, 2021. Shareholders are able to obtain the
definitive proxy statement, any amendments or supplements to the
proxy statement and other documents filed by the Company with the
SEC at no charge at the SEC’s website at www.sec.gov. Copies are
also available at no charge on the Company’s website at
www.mimedx.com.
Contacts
Investors:Jack HowarthInvestor
Relations404-360-5681jhowarth@mimedx.com
Media:Hilary DixonCorporate
& Strategic
Communications404-323-4779hdixon@mimedx.com
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024